Balaxi Pharmaceuticals Limited Share Price

Equities

BALAXI

INE618N01014

Pharmaceuticals

Market Closed - NSE India S.E. 12:43:47 03/05/2024 BST 5-day change 1st Jan Change
599.1 INR -0.61% Intraday chart for Balaxi Pharmaceuticals Limited +2.41% +38.57%

Financials

Sales 2021 2.31B 27.73M 2.21B Sales 2022 2.79B 33.49M 2.67B Capitalization 3.52B 42.14M 3.36B
Net income 2021 381M 4.57M 364M Net income 2022 477M 5.72M 456M EV / Sales 2021 2.28 x
Net Debt 2021 19.9M 239K 19.01M Net cash position 2022 37.39M 448K 35.72M EV / Sales 2022 1.25 x
P/E ratio 2021
13.8 x
P/E ratio 2022
7.38 x
Employees 400
Yield 2021 *
-
Yield 2022
0.14%
Free-Float 89.66%
More Fundamentals * Assessed data
Dynamic Chart
Balaxi Pharmaceuticals Limited Incorporates New Wholly Owned Subsidiary in Chile CI
Balaxi Pharmaceuticals Limited Announces Update on Company's Pharmaceutical Formulation Plant CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Balaxi Pharmaceuticals Limited agreed to acquire Balaxi Healthcare Ecuador S.A.S. for $0.04 million. CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2022 CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021 CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2021 CI
Balaxi Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021 CI
More news
1 day-0.61%
1 week+2.41%
Current month-2.03%
1 month+3.77%
3 months+37.68%
6 months+43.81%
Current year+38.57%
More quotes
1 week
593.50
Extreme 593.5
619.00
1 month
551.20
Extreme 551.2
619.00
Current year
425.00
Extreme 425
686.30
1 year
399.95
Extreme 399.95
686.30
3 years
303.55
Extreme 303.55
747.00
5 years
60.00
Extreme 60
1 080.20
10 years
11.50
Extreme 11.5
1 080.20
More quotes
Managers TitleAgeSince
Chief Executive Officer - 27/09/42
Director of Finance/CFO - 31/12/11
Compliance Officer - 10/10/22
Members of the board TitleAgeSince
Chief Executive Officer - 27/09/42
Founder 51 -
Director/Board Member 42 03/05/17
More insiders
Date Price Change Volume
03/05/24 599.1 -0.61% 2,639
02/05/24 602.8 -1.42% 3,767
30/04/24 611.5 +1.28% 4,032
29/04/24 603.8 +3.21% 9,091
26/04/24 585 +1.68% 3,584

Delayed Quote NSE India S.E., May 03, 2024 at 12:43 pm

More quotes
Balaxi Pharmaceuticals Limited is an India-based company. The Company operates as an intellectual property right (IPR)-based pharmaceutical company. The Company primarily operates in frontier markets across Latin America and Africa. The Company is focusing on frontier markets, with a growing portfolio of drugs across multiple therapeutic segments. It has a portfolio across multiple therapeutic segments, stock & sell models, and supplies branded and generic medicines. The Company’s products include Anti-biotic, Analgesic, Medical Device, Vitamins, Anti-Malaria, Erectile Dysfunction, Hypertension, Anti-Asthma, Steroid, Anti-Helminthic, Anti-Ulcer, Hygiene, Anticholinergic, Dietary Supplement, Diuretic, Hormone, Anti-Emetic, Bronchodilator, Local Anesthetic, Anemia, Anti-Diarrhea, Antihistamine, Hypotension, Antacid, Anti-Tuberculosis, Insect Repellents and Laxative. Its subsidiary is Balaxi Global DMCC, Dubai.
More about the company
  1. Stock Market
  2. Equities
  3. BALAXI Stock